TY  - CHAP
AU  - Fulvio Baggi
AU  - Carlo Antozzi
ED  - Joseph A. Pruitt
Y1  - 2012-01-20
PY  - 2012
T1  - Immunomodulatory Treatments for Myasthenia Gravis: Plasma Exchange, Intravenous Immunoglobulins and Semiselective Immunoadsorption
N2  - Myasthenia gravis is presently an incurable antibody-mediated autoimmune disorder characterized by generalized voluntary skeletal muscle weakness. The cause of the weakness is a defect at the neuromuscular junction level, in which autoimmune antibodies block the receptors responsible for initiating muscular contraction. Literally translated from its Latin and Greek etymological roots, myasthenia gravis means "grave muscle weakness". Fortunately, advances in modern medicine have resulted in a reduction of the truly "grave" outcomes for those inflicted but, without a cure, the gravity surrounding the disease remains
BT  - A Look into Myasthenia Gravis
SP  - Ch. 4
UR  - https://doi.org/10.5772/32045
DO  - 10.5772/32045
SN  - 
PB  - IntechOpen
CY  - Rijeka
Y2  - 2024-04-25
ER  -